Monopar Therapeutics Announces Rolling NDA Submission for Wilson Disease

What Happened
Monopar Therapeutics (MNPR) announced on July 22, 2026, that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for ALXN1840 (tiomolibdate choline) to treat Wilson disease. The company disclosed the news under Regulation FD in a press release that was furnished as Exhibit 99.1 to its Form 8-K.

Key Details

• Filing date: Form 8-K filed July 22, 2026; press release dated July 22, 2026 (Exhibit 99.1).
• Product: ALXN1840 (tiomolibdate choline).
• Indication: Wilson disease.
• Submission type: Rolling NDA to the U.S. FDA (sections submitted as they are completed).

Why It Matters
A rolling NDA submission is a major regulatory milestone showing Monopar has progressed to the formal U.S. approval process for ALXN1840. For investors, this signals advancement toward potential regulatory review and future commercialization steps for a therapy addressing Wilson disease. Monitor Monopar for updates on the NDA completion, FDA review milestones, and any company disclosures about timing, clinical data, or potential commercial plans.